The concurrent mutations of C26N/N53F can reduce the antigenic
propensity of nsLTP2 as an anti-tumor or viral drug carrier
Abstract
Nonspecific Lipid Transfer Proteins (nsLTP2) are small and soluble
proteins, which due to their unique features have the ability of binding
to lipids and some pharmaceutical compounds, are considered as good
options for drug delivery systems. Their stability against proteolysis
and thermal denaturation leads to allergenic reactions which limit its
clinical usage. The bioinformatics approach was carried out to
hydrophobicity and antigenicity analysis of Oryza sativa (Iranian group)
nsLTP2. Using Molegro Virtual Docker software, the affinity and binding
strength of several fatty acids, steroid-based anti-viral, and
anti-tumor drugs with nsLTP2 were identified. Results demonstrated that
there is only one transmembrane segment in the nsLTP2 protein sequence
which is located in the signal peptide region, also calculating the
average antigenicity propensity (AP) of amino acids showed that
concurrent mutations of C26N/N53F can reduce the antigenic propensity of
these proteins. Furthermore, Abacavir (MolDock Score = -119.348), DHA
(MolDock Score = -152.601), and Basedoxifene (MolDock Score = -156.776)
could be considered as the best antiviral, phospholipid, and anticancer
ligands for it, respectively.